These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

95 related items for PubMed ID: 22871369

  • 1. Safety of the long-acting neuraminidase inhibitor laninamivir octanoate hydrate in post-marketing surveillance.
    Kashiwagi S, Yoshida S, Yamaguchi H, Niwa S, Mitsui N, Tanigawa M, Shiosakai K, Yamanouchi N, Shiozawa T, Yamaguchi F.
    Int J Antimicrob Agents; 2012 Nov; 40(5):381-8. PubMed ID: 22871369
    [Abstract] [Full Text] [Related]

  • 2. Safety evaluation of laninamivir octanoate hydrate through analysis of adverse events reported during early post-marketing phase vigilance.
    Nakano T, Okumura A, Tanabe T, Niwa S, Fukushima M, Yonemochi R, Eda H, Tsutsumi H.
    Scand J Infect Dis; 2013 Jun; 45(6):469-77. PubMed ID: 23373850
    [Abstract] [Full Text] [Related]

  • 3. Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza.
    Ikematsu H, Kawai N.
    Expert Rev Anti Infect Ther; 2011 Oct; 9(10):851-7. PubMed ID: 21973296
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Duration of fever and other symptoms after the inhalation of laninamivir octanoate hydrate; comparison of the 2011/12 to 2015/16 Japanese influenza seasons.
    Ikematsu H, Kawai N, Iwaki N, Kashiwagi S.
    J Infect Chemother; 2017 Sep; 23(9):627-633. PubMed ID: 28709902
    [Abstract] [Full Text] [Related]

  • 7. The safety and efficacy of the long-acting neuraminidase inhibitor laninamivir octanoate hydrate for Inhalation Suspension Set in children under the age of 5 in a post-marketing surveillance.
    Nakano T, Yamaguchi H, Chiba T, Shiosakai K, Chikada S, Matsuoka Y.
    J Infect Chemother; 2021 Oct; 27(10):1436-1446. PubMed ID: 34226112
    [Abstract] [Full Text] [Related]

  • 8. Duration of fever and other symptoms after the inhalation of laninamivir octanoate hydrate for influenza treatment; comparison among the four Japanese influenza seasons from 2011-2012 to 2014-2015.
    Ikematsu H, Kawai N, Iwaki N, Kashiwagi S.
    J Infect Chemother; 2016 Sep; 22(9):605-10. PubMed ID: 27493024
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Post-marketing safety and effectiveness evaluation of the intravenous anti-influenza neuraminidase inhibitor peramivir (I): a drug use investigation.
    Komeda T, Ishii S, Itoh Y, Ariyasu Y, Sanekata M, Yoshikawa T, Shimada J.
    J Infect Chemother; 2014 Nov; 20(11):689-95. PubMed ID: 25131292
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Duration of fever and other symptoms after the inhalation of laninamivir octanoate hydrate in the 2016/17 Japanese influenza season; comparison with the 2011/12 to 2015/16 seasons.
    Ikematsu H, Kawai N, Iwaki N, Kashiwagi S, Ishikawa Y, Yamaguchi H, Shiosakai K.
    J Infect Chemother; 2018 Sep; 24(9):718-724. PubMed ID: 29861186
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A meta-analysis of laninamivir octanoate for treatment and prophylaxis of influenza.
    Higashiguchi M, Matsumoto T, Fujii T.
    Antivir Ther; 2018 Sep; 23(2):157-165. PubMed ID: 28869418
    [Abstract] [Full Text] [Related]

  • 17. Laninamivir and its prodrug, CS-8958: long-acting neuraminidase inhibitors for the treatment of influenza.
    Yamashita M.
    Antivir Chem Chemother; 2010 Sep; 21(2):71-84. PubMed ID: 21107016
    [Abstract] [Full Text] [Related]

  • 18. Intrapulmonary Pharmacokinetics of Laninamivir, a Neuraminidase Inhibitor, after a Single Nebulized Administration of Laninamivir Octanoate in Healthy Japanese Subjects.
    Toyama K, Furuie H, Ishizuka H.
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29061751
    [Abstract] [Full Text] [Related]

  • 19. Laninamivir octanoate for post-exposure prophylaxis of influenza in household contacts: a randomized double blind placebo controlled trial.
    Kashiwagi S, Watanabe A, Ikematsu H, Awamura S, Okamoto T, Uemori M, Ishida K.
    J Infect Chemother; 2013 Aug; 19(4):740-9. PubMed ID: 23732307
    [Abstract] [Full Text] [Related]

  • 20. Clinical outcome of laninamivir octanoate hydrate for influenza in the 2013-2014 Japanese season.
    Ikematsu H, Kawai N, Iwaki N, Kashiwagi S.
    J Infect Chemother; 2015 Nov; 21(11):802-7. PubMed ID: 26410550
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.